Grants and Contributions:
Title:
Maximisation of a topical formulation containing an analog of Maresin-1 (MaR102) to treat pain and inflammation in an animal model of Vulvodynia
Agreement Number:
936187
Agreement Value:
$83,372.00
Agreement Date:
Oct 15, 2019 - Dec 31, 2020
Description:
Several published studies have shown the high potency of MaR1 to decrease pain and inflammation in various animal models. The goal of the current project is to demonstrate and improve the capacity of a specific topical formulation containing a synthetic analog of MaR1 to decrease pain and inflammation in a relevant rodent model of vulvodynia.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Quebec, Quebec, CA G1V 0B9
Reference Number:
172-2019-2020-Q3-936187
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
806535035
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 9,800 dollars.
Amendment Date
Nov 9, 2020
Recipient's Legal Name:
Maresins Pharma, inc.
Federal Riding Name:
Louis-Hébert
Federal Riding Number:
24044
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: